Our Journey
2022
Softhale successfully completed its first surveillance audit on ISO 13485, so the license will be retained –
March 20222021
The Board of Directors of Sino Biopharmaceutical Limited announces that on 22 March 2021, invoX Pharma Ltd, a wholly-owned subsidiary of the Company, entered into an agreement in relation to a 100% acquisition of Softhale NV.
2019
Successful series B fundraising –
February 2019
Softhale’s proprietary device technology is protected by 15+ patents. Our portfolio also expanded with a branded high-end product. Our current activities are financed by the successful series B fundraising closed in early 2019.
2018
Internal team growth –
December 2018
In 2018 and 2019, the internal team grew with the recruitment of leading industry experts in the respiratory field with a long track record of bringing inhalable branded and generic products to market.
2017
Softhale’s first laboratory was opened –
August 2017Softhale moves into the office in Diepenbeek, Belgium –
April 20172016
Series A round successfully completed –
December 2016
Completed a successful Series A round, a more than €1 million grant, and a first customer-funded proof-of-concept study.
Softhale NV was established in Diepenbeek, Belgium –
February 20162015
Early-stage proof-of-concept work –
February 20152014
Business plan creation –
January 2014
The team conducted concept validation work and initial freedom-to-operate analysis, followed by the creation of a business plan. This plan helped Softhale raise seed funding.
2013
First patent was filed by the group –
June 20132012
Starting conceptual work on a new generation Soft Mist Inhaler (SMI) –
August 2012
the founding members of Softhale met and started their conceptual work on a new generation Soft Mist Inhaler (SMI). The team had proven expertise in the microfluidic, medical device, pharmaceutical, and business development competencies, and the collaboration resulted in a business concept to start a pharmaceutical company.